#ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody
Weeks after Gilead-partnered Arcus whipped up some cheers from analysts around its small molecule CD73 inhibitor — presenting preliminary data at AACR that “exceeded expectations” — a Chinese biotech is unveiling its own early results using an antibody approach that it says puts more weight behind the target.
I-Mab touted a 23% objective response rate in the US Phase I dose escalation study, among 13 evaluable patients with several different types of advanced cancers. All were given a combination of uliledlimab and Roche’s PD-L1, Tecentriq.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.